Manuela Liguori

Manuela Liguori

Auto-generated profile, based on publicly available information

Manuela Liguori

IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089, Milan, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cancer Cell
Verified
Journal Article
Closed access
Giovanni GermanoGiovanni Germano
Giovanni Germano
RFRoberta Frapolli
Roberta Frapolli
CBCristina Belgiovine
Cristina Belgiovine
Achille AnselmoAchille Anselmo
Achille Anselmo
SPSamantha Pesce
Samantha Pesce
PAPaola Allavena
Paola Allavena

1 July 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GSGraziella Solinas
Graziella Solinas
SSSilvia Schiarea
Silvia Schiarea
MLManuela Liguori
Manuela Liguori
MFMarco Fabbri
Marco Fabbri
SPSamantha Pesce
Samantha Pesce
PAPaola Allavena
Paola Allavena
Tumor-associated macrophages (TAMs) are key orchestrators of the tumor microenvironment directly affecting neoplastic cell growth, neoangiogenesis, and extracellular matrix remodeling. In turn, the tumor milieu strongly influences maturation of TAMs and shapes several of their features. To address the early macrophage (Mϕ) differentiation phase in a malignant context, we mimicked a tumor microenvironment by in vitro coculturing human blood monocytes with conditioned media from different cancer cell lines. Only 2 out of 16 tumor cell lines induced Mϕ differentiation due to secreted M-CSF isoforms, including high molecular mass species. A global gene profiling of tumor-conditioned Mϕ was performed. Comparison with other datasets (polarized M1-Mϕ, M2-Mϕ, and TAMs isolated from human tumors) highlighted the upregulation of several genes also shared by TAM and M2-polarized Mϕ. The most expressed genes were selenoprotein 1, osteoactivin, osteopontin, and, interestingly, migration-stimulating factor (MSF), a poorly studied oncofoetal isoform of fibronectin. MSF (present in fetal/cancer epithelial and stromal cells but not in healthy tissues) was never identified in Mϕ. MSF production was confirmed by immunohistochemistry in human TAMs. MSF was induced by M-CSF, IL-4, and TGFβ but not by proinflammatory stimuli. RNA and protein analysis clearly demonstrated that it is specifically associated with the M2 polarization of Mϕ. Tumor-conditioned Mϕ-derived MSFs strongly stimulated tumor cell migration, thus contributing to the motile phenotype of neoplastic cells. In conclusion, MSF is a new molecule associated with the M2 polarization of Mϕ and expressed by TAMs. Its biological function may contribute to Mϕ-mediated promotion of cancer cell invasion and metastasis.

6 July 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CBCristina Belgiovine
Cristina Belgiovine
EBEzia Bello
Ezia Bello
MLManuela Liguori
Manuela Liguori
ICIlaria Craparotta
Ilaria Craparotta
LMLaura Mannarino
Laura Mannarino
Maurizio D'IncalciMaurizio D'Incalci
Maurizio D'Incalci
Background: Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and the DNA repair machinery in tumour cells. Methods: In this study we investigated whether lurbinectedin has the ability to modulate the inflammatory microenvironment and the viability of myeloid cells in tumour-bearing mice. Results: Administration of lurbinectedin significantly and selectively decreased the number of circulating monocytes and, in tumour tissues, that of macrophages and vessels. Similar findings were observed when a lurbinectedin-resistant tumour variant was used, indicating a direct effect of lurbinectedin on the tumour microenviroment. In vitro, lurbinectedin induced caspase-8-dependent apoptosis of human purified monocytes, whereas at low doses it significantly inhibited the production of inflammatory/growth factors (CCL2, CXCL8 and VEGF) and dramatically impaired monocyte adhesion and migration ability. These findings were supported by the strong inhibition of genes of the Rho-GTPase family in lurbinectedin-treated monocytes. Conclusions: The results illustrate that lurbinectedin affects at multiple levels the inflammatory microenvironment by acting on the viability and functional activity of mononuclear phagocytes. These peculiar effects, combined with its intrinsic activity against cancer cells, make lurbinectedin a compound of particular interest in oncology.

28 September 2011 in Cancers
Verified
Journal Article
Open access
PDF file
MLManuela Liguori
Manuela Liguori
GSGraziella Solinas
Graziella Solinas
Giovanni GermanoGiovanni Germano
Giovanni Germano
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
PAPaola Allavena
Paola Allavena
Tumor-Associated Macrophages (TAM) are key components of the reactive stroma of tumors. In most, although not all cancers, their presence is associated with poor patient prognosis. In addition to releasing cytokines and growth factors for tumor and endothelial cells, a distinguished feature of TAM is their high-rate degradation of the extra-cellular matrix. This incessant stroma remodelling favours the release of matrix-bound growth factors and promotes tumor cell motility and invasion. In addition, TAM produce matrix proteins, some of which are typical of the neoplastic tissues. The gene expression profile of TAM isolated from human tumors reveals a matrix-related signature with the up-regulation of genes coding for different matrix proteins, as well as several proteolytic enzymes. Among ECM components are: osteopontin, osteoactivin, collagens and fibronectin, including also a truncated isoform of fibronectin termed migration stimulation factor. In addition to serve as structural proteins, these matrix components have key functions in the regulation of the vessel network, in the inductionof tumor cell motility and degradation of cellular debris. Among proteolytic enzymes are: matrix metalloproteases, cathepsins, lysosomal and ADAM proteases, and the urokinase-type plasminogen activator. The degrading activity of TAM, coupled to the production of bio-active ECM proteins, co-operate to the build-up and maintenance of an inflammatory micro-environment which eventually promotes tumor progression.

13 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MLManuela Liguori
Manuela Liguori
CBChiara Buracchi
Chiara Buracchi
FPFabio Pasqualini
Fabio Pasqualini
FBFrancesca Bergomas
Francesca Bergomas
SPSamantha Pesce
Samantha Pesce
PAPaola Allavena
Paola Allavena
Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor micro-environment

11 September 2015 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
Fabio GrizziFabio Grizzi
Fabio Grizzi
Elena BorroniElena Borroni
Elena Borroni
AVAlessandro Vacchini
Alessandro Vacchini
DQDorina Qehajaj
Dorina Qehajaj
MLManuela Liguori
Manuela Liguori
AIAntonio Di Ieva
Antonio Di Ieva
Pituitary Adenoma and the Chemokine Network: A Systemic View